BioSpace News Archive

Gameto announced encouraging new findings from a study evaluating how minimal controlled ovarian stimulation in combination with Fertilo, their novel investigational in vitro maturation solution containing engineered ovarian support cells to mature eggs outside of the body, affected patients’ egg retrieval experiences when compared to conventional stimulation.

Mosaic Biosciences announced two strategic leadership additions to its team: Malavi Madireddi, PhD, as Senior Vice President, Drug Discovery, and Scott Glaser, PhD, as Senior Vice President, Biologics Discovery.

Watchmaker Genomics, a provider of innovative solutions for molecular analysis, announced the launch of a high-purity RNase Inhibitor that is well-suited for a wide range of applications where maintaining RNA integrity is critical, including single-cell and single-nuclei sequencing, as well as pathogen detection.

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., announced the launch of the Shasta™ Single-Cell System, an automated, high-throughput NGS solution with well-validated chemistries and intuitive bioinformatics tools that enables novel biomarker discovery for oncology research.

Genetesis, Inc., a leader in the field of magnetocardiography (MCG), today announced that official results from its MAGNETO trial were published in a special issue of the American Heart Journal Plus: Cardiology Research and Practice.

Alexion Pharma Canada Corp., AstraZeneca’s Rare Disease group, is pleased to announce the appointment of Karen Heim as Vice President and General Manager, Canada, effective April 1st, 2024.

EarliTec Diagnostics, Inc. announced today a $21.5 million Series B financing round, led by Nexus NeuroTech Ventures and Venture Investors Health Fund.

Odyssey Therapeutics, Inc. today announced the appointment of Julie Clauss, MBA, as chief operating officer and Christopher Butler, Ph.D., as senior vice president (SVP), head of Chemistry.

Juniper Biomedical announced today that it has successfully completed an oversubscribed $2M Series Seed financing and also has been awarded $1M through the NIH Common Fund as a winner of the NIH SPARC Neuromod Prize.

Qlaris Bio, Inc. today announced the initiation and dosing of two separate U.S. Phase II masked, randomized clinical trials investigating QLS‑111 in patients with ocular hypertension and glaucoma.